Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326 is registered in ClinicalTrials.gov with Actelion as lead sponsor.

NCT NCT01093326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01093326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis
Lead sponsor
Actelion
Phase
Phase 2
Overall status
Completed
Start date
May 12, 2010
Completion date
September 6, 2023
Enrollment
353 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis